The enactment of S0799 is expected to directly affect the calculations and policies health insurers and pharmacy benefit managers utilize in relation to their coverage. This will specifically apply to new health plans initiated or modified after January 1, 2024. By requiring comprehensive inclusion of all cost contributions by the enrollee, the legislation could lead to better alignment between individuals' actual medical expenses and their insurance coverage, thus promoting fairer treatment in health insurance practices.
Summary
S0799 is a legislative act aimed at amending the Rhode Island General Laws related to prescription drug benefits. The primary focus of this bill is to redefine how cost-sharing for prescription drugs is calculated under health plans. By including all amounts paid by the enrollee or on their behalf by another party when determining an enrollee's contributions to out-of-pocket maximum costs, the bill seeks to enhance transparency and potentially reduce financial burdens on individuals seeking necessary medications.
Contention
While the bill aims to improve clarity and fairness in the healthcare system, there may be concerns among stakeholders regarding how this change impacts the overall costs borne by insurance providers. There could be apprehension from insurance companies regarding increased liabilities, leading to higher premiums for consumers. Furthermore, debates could arise regarding the practical implications for pharmacy benefit managers in adapting their existing frameworks to comply with the new calculation methods outlined in the legislation.
An act to amend Section 4073.5 of the Business and Professions Code, to amend Section 1367.22 of the Health and Safety Code, and to add Section 10123.190 to the Insurance Code, relating to prescription drugs.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of medical tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Prohibits pre-approval or precertification of cancer treatments, tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.